Cyclosporine Or Derivative Utilizing Patents (Class 514/20.5)
-
Publication number: 20130345150Abstract: An ophthalmic composition comprising a polyaphron dispersion.Type: ApplicationFiled: March 14, 2012Publication date: December 26, 2013Inventor: Fraser Steele
-
Publication number: 20130337019Abstract: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.Type: ApplicationFiled: August 2, 2013Publication date: December 19, 2013Applicant: NOVAGALI PHARMA SAInventors: LAURA RABINOVICH-GUILATT, GREGORY LAMBERT, FREDERIC LALLEMAND, BETTY PHILIPS
-
Publication number: 20130338083Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.Type: ApplicationFiled: August 14, 2013Publication date: December 19, 2013Applicant: Allergan, Inc.Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
-
Publication number: 20130338082Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.Type: ApplicationFiled: August 7, 2013Publication date: December 19, 2013Applicant: Allergan, Inc.Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
-
Publication number: 20130331340Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.Type: ApplicationFiled: August 14, 2013Publication date: December 12, 2013Applicant: Alllergan, Inc.Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
-
Publication number: 20130331338Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.Type: ApplicationFiled: August 7, 2013Publication date: December 12, 2013Applicant: Allergan, Inc.Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
-
Publication number: 20130331336Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.Type: ApplicationFiled: August 7, 2013Publication date: December 12, 2013Applicant: Allergan, Inc.Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
-
Publication number: 20130331339Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.Type: ApplicationFiled: August 14, 2013Publication date: December 12, 2013Applicant: Allergan, Inc.Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
-
Publication number: 20130331337Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.Type: ApplicationFiled: August 7, 2013Publication date: December 12, 2013Applicant: Allergan, Inc.Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
-
Publication number: 20130331341Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.Type: ApplicationFiled: August 14, 2013Publication date: December 12, 2013Applicant: Allergan, Inc.Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
-
Publication number: 20130330411Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. 10].Type: ApplicationFiled: July 15, 2013Publication date: December 12, 2013Inventor: Ivan Coulter
-
Publication number: 20130323270Abstract: The present invention relates to a cyclosporine emulsion containing: i) a cyclosporine ii) a natural oil (long chain triglyceride) iii) a phosphatidylcholine, iv) glycerol, v) a pharmaceutically tolerable alkali salt of a free fatty acid, vi) a medium chain triglyceride-oil vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment viii) water.Type: ApplicationFiled: September 30, 2011Publication date: December 5, 2013Applicant: NeuroVive Pharmaceutical ABInventor: Eskil Elmér
-
Publication number: 20130324481Abstract: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably ?-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.Type: ApplicationFiled: August 9, 2013Publication date: December 5, 2013Applicant: Ramscor, Inc.Inventors: Vernon G. Wong, Louis L. Wood
-
Publication number: 20130324480Abstract: The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.Type: ApplicationFiled: May 30, 2013Publication date: December 5, 2013Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, William R. Carling, Michael E. Garst
-
Publication number: 20130323295Abstract: Provided are compositions containing engineered particles, and methods of making such engineered particles. Polymeric articles, such as contact lenses, prepared from such compositions are also provided. Such engineered particles are dispersible in hydrophilic systems such as monomer systems for preparation of contact lenses. Each of the engineered particles comprises a hydrophobic core and a hydrophilic shell. The hydrophobic core comprises a silicone-based polymer that can have multiple cross-links and/or polymer-polymer entanglement, and the hydrophilic shell is formed from a reactive stabilizer. A residue of the reactive stabilizer or a hydrophilic segment of the reactive stabilizer can form the shell. The particles have an average particle size of less than about 500 nm.Type: ApplicationFiled: November 20, 2012Publication date: December 5, 2013Applicant: Johnson & Johnson Vision Care, Inc.Inventor: Johnson & Johnson Vision Care, Inc.
-
Publication number: 20130316961Abstract: The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome.Type: ApplicationFiled: October 24, 2011Publication date: November 28, 2013Applicants: UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (Institut National de la Santé et de la Recherche Médicale)Inventors: Jean-Christophe Roux, Laurent Villard, Frédéric Saudou
-
Publication number: 20130315981Abstract: The present invention is a method of increasing lipolysis in an adipose tissue of a mammal comprising delivering to macrophages at the adipose tissue of the mammal an effective amount of an agent which reduces the concentration of macrophages at the adipose tissue of the mammal, thereby increasing lipolysis in the adipose tissue of the mammal.Type: ApplicationFiled: June 22, 2011Publication date: November 28, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventors: Anthony W. Ferrante, JR., Aliki Kosteli
-
Publication number: 20130303462Abstract: The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.Type: ApplicationFiled: May 13, 2013Publication date: November 14, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Thomas KLEIN, Maximilian von EYNATTEN, Berthold HOCHER, Michael MARK, Yuliya SHARKOVSKA
-
Patent number: 8575108Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.Type: GrantFiled: November 15, 2007Date of Patent: November 5, 2013Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Patent number: 8568748Abstract: The present invention relates to a pharmaceutical formulation in colloidal form for topical application for the therapy and prophylaxis of pathological changes of the skin and/or integumentary structures of the skin and/or mucous membranes, including mucous membranes of the digestive tract, uro-genital tract and bronchial system and/or conjunctiva, containing a lipophilic phase in a quantity of 1-10% by weight, a mixture of surfactant and co-surfactant in a quantity of 1-50% by weight, a hydrophilic phase in a quantity of 40-80% by weight and, as active ingredient, cyclosporin and/or derivatives thereof in a concentration of 0.1-20% by weight.Type: GrantFiled: December 14, 2001Date of Patent: October 29, 2013Assignee: JAGOTEC AGInventors: Johannes Wohlrab, Reinhard Neubert, Konstanze Jahn
-
Patent number: 8563518Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.Type: GrantFiled: June 28, 2012Date of Patent: October 22, 2013Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Publication number: 20130266663Abstract: Methods for treating a condition associated with proteoglycan production in a mammal are provided. The methods comprise the administration of at least one of a calmodulin antagonist, a transient receptor potential (TRP) channel inhibitor and a calmodulin-binding peptide to the mammal.Type: ApplicationFiled: April 29, 2011Publication date: October 10, 2013Inventors: Arthur Brown, Sandy Gian Vascotto
-
Publication number: 20130267472Abstract: This invention concerns an aqueous ophthalmic solution containing an immunosuppressive agent, such as cyclosporin A, and at least three polymers. The three polymers are preferably a combination of a cellulose derivative, a polyvinyl derivative, and a macrogolglycerol hydroxystearate.Type: ApplicationFiled: March 12, 2013Publication date: October 10, 2013Applicant: LABORATOIRES THEAInventors: Emmanuel Muriaux, Fabrice Mercier
-
Patent number: 8551952Abstract: Provided herein are methods for treatment of ocular diseases. The methods comprise administering a compound of general Formula (I): wherein R1, R2, R3, R4 and Ak are as defined in the specification.Type: GrantFiled: April 27, 2012Date of Patent: October 8, 2013Assignee: Scynexis, Inc.Inventor: David Renwick Houck
-
Publication number: 20130243794Abstract: The invention provides methods for determining the propensity to develop, or the presence of, one or more infection-induced illness(es). The invention further provides methods of treating an infection (e.g., bacterial infection), methods of diagnosing an infection-induced illness in a subject, and methods of predicting the future severity of one or more infection-induced illness(es). Also provided are kits for determining the likelihood or propensity of a subject to develop one or more infection-induced illness(es) and kits for diagnosing one or more infection-induced illness(es) in a subject and identifying a subject as having an increased risk of later developing one or more severe infection-induced illness(es).Type: ApplicationFiled: December 5, 2011Publication date: September 19, 2013Applicant: Beth Israel Deaconess Medical Center, Inc.Inventor: Carl J. Hauser
-
Publication number: 20130244952Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.Type: ApplicationFiled: October 11, 2012Publication date: September 19, 2013Applicant: Abraxis BioScience, LLCInventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
-
Patent number: 8536134Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.Type: GrantFiled: February 28, 2007Date of Patent: September 17, 2013Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Patent number: 8524671Abstract: The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.Type: GrantFiled: May 21, 2010Date of Patent: September 3, 2013Assignee: Allergan, IncInventors: Michael E. Garst, Michael E. Stern
-
Publication number: 20130224151Abstract: The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors alone or in combination for the treatment or prevention of abdominal, visceral or pelvic pain. Also described herein are pharmaceutical compositions comprising a FAAH inhibitor, alone or in combination with an additional therapeutic agent for the treatment of abdominal, visceral or pelvic pain.Type: ApplicationFiled: March 31, 2011Publication date: August 29, 2013Applicants: UNITED STATES OF AMERICA, IRONWOOD PHARMACEUTICALS, INCInventors: James Philip Pearson, Mark G. Currie, Yvette Tache, Muriel Larauche
-
Publication number: 20130210704Abstract: The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: S&T GLOBAL INC.Inventor: S&T Global Inc.
-
Patent number: 8501174Abstract: Therapeutic methods are disclosed herein.Type: GrantFiled: June 28, 2010Date of Patent: August 6, 2013Assignee: Allergan, Inc.Inventors: Gregg Feinerman, Neil Barth, Rhett M. Schiffman, Pamela S. Barnett
-
Publication number: 20130195769Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.Type: ApplicationFiled: March 11, 2013Publication date: August 1, 2013Applicant: FOAMIX LTD.Inventor: Foamix Ltd.
-
Publication number: 20130190223Abstract: The compounds of the present invention are non-immunosupressive cyclosporine analogue molecules that are able to bind cyclophilin. Said compounds include a modified side chain of amino acid I of cyclosporin A, consisting of an oxyalkyl having substituents R?, R1 and R2, where R? is H or Acetyl; R1 is a saturated or unsaturated straight chain or branched aliphatic carbon chain; and R2 may be a hydrogen; a unsubstituted, N substituted or NN disubstituted amide; a N substituted or unsubstituted acyl protected amine; a carboxylic acid; a N substituted or unsubstituted amine; a nitrile; a ester; a ketone; a hydroxy, dihydroxy, trihydroxy or polyhydroxy alkyl; or a substituted or unsubstituted aryl.Type: ApplicationFiled: July 3, 2009Publication date: July 25, 2013Applicant: ISOTECHNIKA PHARMA INC.Inventors: Alexander Hegmans, Bruce W. Fenske, David P. Czajkowski, Darren R. Ure, Shin Sugiyama, Dan J. Trepanier, David H. McGlade, Mark D. Abel
-
Publication number: 20130189246Abstract: Provided are compositions and methods for treatment of ophthalmic conditions, such as retinal detachment and age-related macular degeneration. Various fluorenone derivatives described herein can stimulate fluid removal from the subretinal space and down-regulate reactive gliosis. Administration of compounds described herein can provide an alternative or an adjunct to an invasive procedure to reattach the retina.Type: ApplicationFiled: November 5, 2010Publication date: July 25, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventor: Konstantin Petrukhin
-
Publication number: 20130190252Abstract: The present invention relates to an improved pharmaceutical composition and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of a lipophilic active ingredient with milk as a solubilizing/dispersing agent and methods for the preparation thereof.Type: ApplicationFiled: March 6, 2013Publication date: July 25, 2013Applicant: PHARMATHEN S.A.Inventor: PANAYOTIS MACHERAS
-
Publication number: 20130183267Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.Type: ApplicationFiled: January 4, 2013Publication date: July 18, 2013Applicant: Enanta Pharmaceuticals, Inc.Inventor: Enanta Pharmaceuticals, Inc.
-
Publication number: 20130177626Abstract: The invention relates to liquid pharmaceutical compositions containing: a) a therapeutically effective dose of a cyclosporin; b) an aqueous carrier liquid; c) a first solubilizing substance selected among the group of phospholipids; and d) a second solubilizing substance selected among the group of non-ionic surfactants. Preferably, the cyclosporin is liposome solubilized. The inventive composition is suitable for oral, parenteral, nasal, mucosal, topical, and particularly pulmonary application in the form of an aerosol.Type: ApplicationFiled: December 4, 2012Publication date: July 11, 2013Applicant: PARI PHARMA GMBHInventor: PARI Pharma GmbH
-
Publication number: 20130177609Abstract: An ophthalmic composition comprises an ophthalmic drug that has a low solubility in water and a surfactant, wherein the ophthalmic drug is present at a concentration from about 3 to about 7000 times the solubility of the drug in water. A volume of about 1-15 microliter is administered topically to an eye of a subject to treat or control a condition for which the drug is effective.Type: ApplicationFiled: February 27, 2013Publication date: July 11, 2013Inventor: Bausch & Lomb Incorporated
-
Publication number: 20130172268Abstract: An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline.Type: ApplicationFiled: February 26, 2013Publication date: July 4, 2013Applicant: INCEPT, LLCInventor: Incept, LLC
-
Publication number: 20130171268Abstract: The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to ameliorate mitochondrial toxicity caused by administration of a chemical, food, or drug.Type: ApplicationFiled: June 5, 2012Publication date: July 4, 2013Inventors: Francisco Villarreal, Alan Maisel, George Schreiner, Guillermo M. Ceballos Reyes, Pam Taub
-
Patent number: 8470784Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: GrantFiled: August 23, 2010Date of Patent: June 25, 2013Assignee: Stealth Peptides International, Inc.Inventors: Liping Liu, Shibo Tang, Xiaoling Liang
-
Publication number: 20130150311Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions.Type: ApplicationFiled: December 13, 2011Publication date: June 13, 2013Inventors: Grzegorz Pietrzynski, Valery Alakhov, Kishore Patel
-
Publication number: 20130142807Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.Type: ApplicationFiled: January 25, 2013Publication date: June 6, 2013Applicant: Rigel Pharmaceuticals, Inc.Inventor: Rigel Pharmaceuticals, Inc.
-
Patent number: 8450281Abstract: The present invention relates to the use of a nonimmunosuppressive cyclosporin A derivative for reducing mitochondrial dysfunction and the rate of apoptosis of muscle cells of patients diagnosed with Ullrich congenital muscular dystrophy or Bethlem myopathy.Type: GrantFiled: January 3, 2008Date of Patent: May 28, 2013Assignee: Debiopharm S.A.Inventors: Paolo Bernardi, Gregoire Vuagniaux, Rafael Crabbe
-
Publication number: 20130123193Abstract: Disclosed herein are methods of making cyclosporin A Form 2.Type: ApplicationFiled: November 14, 2012Publication date: May 16, 2013Applicant: ALLERGAN, INC.Inventors: Ke Wu, Scott W. Smith
-
Publication number: 20130123195Abstract: Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel.Type: ApplicationFiled: November 14, 2012Publication date: May 16, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130123194Abstract: Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.Type: ApplicationFiled: November 14, 2012Publication date: May 16, 2013Applicant: ALLERGAN, INC.Inventors: Wendy M. Blanda, Hongwen M. Rivers, David A. Marsh, Michelle Luu
-
Publication number: 20130122059Abstract: Disclosed herein are methods of formulating cyclosporin A Form 2.Type: ApplicationFiled: November 14, 2012Publication date: May 16, 2013Applicant: ALLERGAN, INC.Inventors: Anuradha Gore, Prem Swaroop Mohanty, E. Quinn Farnes
-
Patent number: 8435520Abstract: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.Type: GrantFiled: February 11, 2011Date of Patent: May 7, 2013Inventors: Hendrik J. Schuurman, Emanuele Luigi Maria Cozzi, Francoise Richard, Guy Taccard, David James Graham White, Peter John Friend, John Wallwork, Paolo Brenner
-
Publication number: 20130108573Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 26, 2012Publication date: May 2, 2013Applicant: Lumena Pharmaceuticals, Inc.Inventor: Lumena Pharmaceuticals, Inc.